A real-world, multicenter, cohort study assessing the efficacy and safety of ustekinumab maintenance therapy for up to 52 weeks in patients with active ulcerative colitis in a GETAID centre
Latest Information Update: 02 Aug 2021
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary) ; Vedolizumab
- Indications Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 02 Aug 2021 New trial record
- 23 Jul 2021 Results published in the Alimentary Pharmacology and Therapeutics